Top Markets
Coin of the day
AIxCrypto Holdings, Inc. AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc.

AIXC
Rank in Stocks #27458
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company... AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Share Price
$1.62
Last synced: 2026-08-19
Market Cap
$32.77M
Change (1 day)
22.67%
Change (1 year)
-13.87%
Country
US
Trade AIxCrypto Holdings, Inc. (AIXC)

Category

P/S ratio for AIxCrypto Holdings, Inc. (AIXC)
P/S ratio as of 2026 TTM: 0
According to AIxCrypto Holdings, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for AIxCrypto Holdings, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors